Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_John Orwin_2023
VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots:John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with XencorHe also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platformThe interview gives an understanding of Atreca’s focus on…
June 20, 2023

Read more

VIEWPOINTS_Philippe Halfon_2023
VIEWPOINTS

Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma

Shots:Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent)He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC aloneThe interview gives an…
June 15, 2023

Read more

VIEWPOINTS_Eric Halioua_2023
VIEWPOINTS

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

Shots:Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung CancerThe results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidateThe interview shows PDC*line’s vision…
June 1, 2023

Read more

VIEWPOINTS_Monica Mann_2023
VIEWPOINTS

Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Shots:Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meetingThe highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiativesThe interview shows how Biogen develops, and delivers…
May 31, 2023

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]